Assessment of the effectiveness of PAH-specific therapy, including selexipag, in patients with idiopathic pulmonary hypertension according to a comprehensive examination using Raman spectroscopy
Aim: to assess the effectiveness of PAH-specific therapy, including selexipag, based on data from a comprehensive examination and assessment of oxygen transport function in patients with IPAH using Raman spectroscopy.Materials and methods. The study was performed on fourteen (n=14) patients diagnose...
Saved in:
Main Authors: | E. S. Allakhverdiev, E. A. Rezukhina, O. V. Slatinskaya, O. V. Rodnenkov, Zh. V. Bochkova, N. A. Brazhe, G. V. Maksimov, T. V. Martynyuk |
---|---|
Format: | Article |
Language: | Russian |
Published: |
InterMedservice
2023-11-01
|
Series: | Евразийский Кардиологический Журнал |
Subjects: | |
Online Access: | https://www.heartj.asia/jour/article/view/6426 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Possibility of evaluation of oxygen transport function in PAH patients on effective selexipag-based therapy
by: E. S. Allakhverdiev, et al.
Published: (2023-10-01) -
Prostacyclin receptor agonist selexipag in a patient with high-risk idiopathic pulmonary arterial hypertension: a case report
by: E. A. Rezukhina, et al.
Published: (2021-09-01) -
Patient and disease characteristics of pulmonary arterial hypertension patients for prostacyclin receptor agonist selexipag treatment initiation
by: E. A. Rezukhina, et al.
Published: (2023-03-01) -
CASE REPORT ON THE SUCCESSFUL USE OF A NEW SELECTIVE PROSTACYCLIN IP RECEPTOR AGONIST, SELEXIPAG, IN A PATIENT WITH IDIOPATHIC PULMONARY HYPERTENSION
by: Z. S. Valieva, et al.
Published: (2019-12-01) -
New treatment options for pulmonary arterial hypertension — the first selective IP-receptor agonist selexipag
by: N. V. Ilyin, et al.
Published: (2019-12-01)